Abstract

Understanding the factors that influence people’s decisions regarding vaccination is essential to promote vaccination. We aimed to clarify the motivations for receiving booster vaccines. We conducted a paper-based questionnaire distributed during January–February 2022 involving students and faculty staff who received the first COVID-19 vaccination at the mass vaccination program during June–September 2021 at Keio University. A total of 1725 participants were enrolled, and all completed the survey. Among these, 64.9% reported a significant adverse event (AEs) affecting daily life after the second vaccine. “Fear of severe COVID-19 illness” (72.6%) was the most common reason for getting vaccinated, followed by “concern of infecting others” (68.4%) and “fear of COVID-19 infection itself” (68.3%). Television emerged as the most influential source of information (80%), followed by university information (50.2%) and social networking sites (42.8%). Multivariate analysis revealed “fear of severe COVID-19 illness”, “fear of COVID-19 infection itself”, and “trust in the efficacy and safety of the vaccines in general” were significantly correlated with willingness to receive paid vaccinations. The severity of AEs and source of information were not related to participants’ willingness to receive booster vaccinations. Participants with positive reasons for vaccination were more likely to accept a third dose.

Details

Title
Factors affecting motivation for receiving a booster dose of the COVID-19 vaccine among Japanese university students and staff: a cross-sectional questionnaire survey
Author
Uchida, Sho 1 ; Uno, Shunsuke 1 ; Kondo, Masahiro 2 ; Uwamino, Yoshifumi 3 ; Namkoong, Ho 1 ; Nishimura, Tomoyasu 4 ; Misawa, Kana 5 ; Kashimura, Shoko 1 ; Yamato, Kei 1 ; Ishizaka, Tamami 1 ; Nagashima, Kengo 6 ; Kitagawa, Yuko 7 ; Hasegawa, Naoki 1 

 Keio University School of Medicine, Department of Infectious Diseases, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
 Keio University Hospital, Biostatistics Unit, Clinical and Translational Research Center, Tokyo, Japan (GRID:grid.412096.8) (ISNI:0000 0001 0633 2119); Keio University, Graduate School of Health Management, Kanagawa, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
 Keio University School of Medicine, Department of Infectious Diseases, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959); Keio University School of Medicine, Department of Laboratory Medicine, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
 Keio University Health Center, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
 Keio University School of Medicine, Department of Infectious Diseases, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959); Keio University Faculty of Pharmacy, Division of Pharmacodynamics, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
 Keio University Hospital, Biostatistics Unit, Clinical and Translational Research Center, Tokyo, Japan (GRID:grid.412096.8) (ISNI:0000 0001 0633 2119) 
 Keio University School of Medicine, Department of Surgery, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
Pages
8009
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3033763333
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.